Metrics to compare | 688759 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688759PeersSector | |
|---|---|---|---|---|
P/E Ratio | −92.3x | 31.9x | −0.4x | |
PEG Ratio | - | 0.27 | 0.00 | |
Price/Book | 9.7x | 2.2x | 2.6x | |
Price / LTM Sales | - | 6.0x | 3.0x | |
Upside (Analyst Target) | - | 31.1% | 54.6% | |
Fair Value Upside | Unlock | 6.7% | 9.7% | Unlock |
BeBetter Med Inc., a biopharmaceutical company, engages in the research and development, and sale of drugs for oncology, metabolic diseases and central nervous system degenerative diseases. It offers BEBT-908, a PI3K/HDAC dual-target small molecule inhibitor for antitumor; developing BEBT-209, a CDK4/6 selective inhibitor for metastatic triple-negative breast cancer; and BEBT-109, a selective EGFR inhibitor designed for NSCLC. The company also develops BEBT-503, an oral, well-balanced pan-PPAR for metabolic diseases including diabetes and mash; BEBT-507, a GalNAc-siRNA drug for Polycythemia Vera (PV); and BEBT-701, a GalNAc-siRNA therapeutic for treatment of hypertension with co-existing hyperlipidemia. In addition, it provides BEBT-809, a small molecule inhibitor for obesity; BEBT-706, for ASCVD risk reduction; BEBT-720, for mash; BEBT-758, for the treatment of Parkinson's disease; BEBT-756, for Alzheimer's disease; BEBT-730, for hyperuricemia and gout; BEBT-733, for renal anemia/CKD; and BEBT-738, for diabetes. The company was founded in 2012 and is based in Guangzhou, China.